<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-109454</identifier>
<setSpec>0003-3170</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Changes in clinical practice after the introduction of removable inferior vena cava filters</dc:title>
<dc:description xml:lang="en">Objectives: To assess whether the introduction of removable inferior vena cava filters (VCF) has led to variations in the number of implants, indications, and immediate complications in our hospital. Materials and methods: The study included consecutive patients (n=88, mean age 68 years, males 46%) with DVT (n=27, 30.7%), PE (n=22, 25%) or both (n=39, 44.3%) who had a VCF implanted by vascular surgeons between 1996-2011. Since 2004 all VCF were potentially removable (OptEase / Cordis). Indications DVT / PE recurrent / progressive with proper anticoagulation (n=22, 25%), DVT / PE with contraindication to anticoagulation (n=47, 53.4%), or removal of anticoagulation after DVT / PE for major surgery (n=19, 21.6%). Results: A total of 88 VCF were implanted: 33 permanent (20 Venatech-LGM/Braun, 13 Trapesase / Cordis), and 55 removable (OptEase / Cordis). Since the introduction of removable VCF, the number of implants increased by 40%, indications for anticoagulation after withdrawal of DVT / PE for major surgery increased (P=0.001) and the indications for DVT / PE recurrent / progressive (P&lt;.001) decreased. Thirty-one (65%) of supposedly temporary VCF (n=48) were not removed. Removal was more likely if implanted in surgery (P&lt;0.001) and less if it was for DVT / PE recurrent / progressive (P&lt;0.06). There were no immediate complications associated with the procedure. Conclusions: The availability of removable FVC has resulted in a higher number of implants, especially in patients with DVT / PE where anticoagulation should be discontinued for major surgery, and probably before that it was delayed until after the acute phase of PE / DVT. Although removable VCF are equally safe in the short term, a significant percentage of those with suspected temporary indications are eventually withdrawn, so its  indication should not be widened(AU)</dc:description>
<dc:creator>Mellado Joan, M</dc:creator>
<dc:creator>Calsina Juscafresa, L</dc:creator>
<dc:creator>Clarà Velasco, A</dc:creator>
<dc:creator>Paredes Mariñas, E</dc:creator>
<dc:creator>Mateos Torres, E</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivos: Evaluar si la introducción de filtros de vena cava (FVC) retirables en nuestra institución ha comportado variaciones en el número de implantes, indicaciones o complicaciones inmediatas. Material y métodos: Pacientes consecutivos (n=88; edad media 68; varones 46%) con TVP (n=27, 30,7%), TEP (n=22, 25%) o ambos (n=39, 44,3%), en quienes se implantó un FVC por cirujanos vasculares entre 1996-2011. A partir de 2004 todos los FVC fueron potencialmente retirables (Optease/Cordis). Indicaciones: TVP/TEP recurrente/progresivo con anticoagulación correcta (n=22, 25%), TVP/TEP con contraindicación para anticoagulación (n=47, 53,4%), o retirada de anticoagulación tras TVP/TEP por cirugía mayor (n=19, 21,6%). Resultados: Se implantaron 88 FVC: 33 permanentes (20 Venatech-LGM/Braun, 13 Trapesase/Cordis) y 55 retirables (Optease/Cordis). Desde la introducción de los FVC retirables, han aumentado un 40% los implantes, las indicaciones por retirada de anticoagulación tras TVP/TEP para cirugía mayor (p=0,001), y disminuido las indicaciones por TVP/TEP recurrente/progresivo (p&lt;0,001). No se retiraron 31 (65%) de los FVC retirables con indicación supuestamente temporal (n=48), siendo más probable la retirada si se implantaba por cirugía mayor (p&lt;0,001) y menos si era por TVP/TEP recurrente/progresivo (p=0,06). No hubo complicaciones inmediatas asociadas al procedimiento. Conclusiones: La disponibilidad de FVC retirables ha comportado un aumento del número de implantes, sobre todo en pacientes con TVP/TEP en los que debe suspenderse la anticoagulación por cirugía mayor y en los que probablemente antes se demoraba esta hasta pasada la fase aguda del TEP/TVP. A pesar de que los FVC retirables son igualmente seguros a corto plazo, un porcentaje relevante de estos con supuesta indicación temporal no son finalmente retirados, por lo que no debería liberalizarse su indicación(AU)</dc:description>
<dc:source>Angiologia;65(1): 10-15, ene.-feb. 2013. tab, ilus</dc:source>
<dc:identifier>ibc-109454</dc:identifier>
<dc:title xml:lang="es">Cambios en la práctica clínica tras la introducción de los filtros de vena cava retirables</dc:title>
<dc:subject>^d33768^s22012</dc:subject>
<dc:subject>^d29148^s22066</dc:subject>
<dc:subject>^d29148^s22074</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d33768^s22016</dc:subject>
<dc:subject>^d29148^s22048</dc:subject>
<dc:subject>^d23232^s22066</dc:subject>
<dc:subject>^d23232^s22045</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d12092^s22016</dc:subject>
<dc:subject>^d12092^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>201302</dc:date>
</metadata>
</record>
</ibecs-document>
